| 1. |
- Arvidsson, Susanne, et al.
(författare)
-
A background to the challenges in managing sustainable business
- 2019
-
Ingår i: Challenges in Managing Sustainable Business : Reporting, Taxation, Ethics and Governance - Reporting, Taxation, Ethics and Governance. - 9783319932651 - 9783319932668
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 2. |
|
|
| 3. |
- Arvidsson, Susanne, et al.
(författare)
-
An exposé of the challenging practice development of sustainability reporting : From the first wave to the EU directive (2014/95/EU)
- 2019
-
Ingår i: Challenges in Managing Sustainable Business : Reporting, Taxation, Ethics and Governance - Reporting, Taxation, Ethics and Governance. - Cham : Springer International Publishing. - 9783319932651 - 9783319932668 ; , s. 3-24
-
Bokkapitel (refereegranskat)abstract
- This chapter sets out to give an exposé of how sustainability reporting has developed into a global reporting practice. It gives a theoretical background to why companies (should) engage in sustainability reporting. Three arguments for providing sustainability reporting are at focus i) gaining, maintaining and/or repairing legitimacy, ii) improving stakeholder relations and iii) decreasing information asymmetry. Although sustainability reporting today has become a global reporting practice, this practice has been criticised throughout the years. The chapter highlights different types of critique: critique against companies’ engagement in sustainability activities per se, critique against sustainability reporting being mere window-dressing (green-, blue- or even SDG-washing) and critique against the poor informational quality of sustainability reporting. This leads the way to a focus on how a new set of voluntary-sustainability standards has been developed to help companies to implement, manage and report on sustainability activities. Using the framework by Behnam and MacLean (2011), three types of voluntary-sustainability standards are discussed: principle-, reporting- and certification-based standards. Attempts to develop mandatory requirements are also at focus in this discussion. In the latter part of the chapter, a financial market perspective is put on sustainability reporting. This reveals how the scepticism among the actors on the financial markets has decreased as the global sustainable investment market has increased. The chapter ends with highlighting the EU Directive (2014/95/EU), which from financial year 2017 mandates the largest EU companies to provide sustainability information in their corporate reports. This raises the question, whether the Directive will be able to enhance the informational quality of sustainability reporting.
|
|
| 4. |
- Arvidsson, Susanne, et al.
(författare)
-
Sustainability reporting
- 2019
-
Ingår i: The 1st SUBREA Conference Report: A focus on challenges and future knowledge-needs. - Lund : Media-Tryck, Lund University. - 9789172674080 - 9789172674097
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 5. |
|
|
| 6. |
- Blomkvist, Marita, 1959, et al.
(författare)
-
Anticorruption
- 2019
-
Ingår i: 1 st SUBREA Conference Report: A focus on challenge and future knowledge-needs. - Lund : Lund University. - 9789172674080 - 9789172674097
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 7. |
- Jonäll, Kristina, 1964, et al.
(författare)
-
Fair taxation, tax transparency and disclosure rules
- 2019
-
Ingår i: The 1st SUBREA Conference Report: A focus on challenges and future knowledge-needs. - Lund : Media-Tryck, Lund University. - 9789172674080 - 9789172674097
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 8. |
- Borgegard, Tomas, et al.
(författare)
-
Alzheimers Disease: Presenilin 2-Sparing gamma-Secretase Inhibition Is a Tolerable A beta Peptide-Lowering Strategy
- 2012
-
Ingår i: Journal of Neuroscience. - : Society for Neuroscience. - 0270-6474 .- 1529-2401. ; 32:48, s. 17297-17305
-
Tidskriftsartikel (refereegranskat)abstract
- gamma-Secretase inhibition represents a major therapeutic strategy for lowering amyloid beta (A beta) peptide production in Alzheimers disease (AD). Progress toward clinical use of gamma-secretase inhibitors has, however, been hampered due to mechanism-based adverse events, primarily related to impairment of Notch signaling. The gamma-secretase inhibitor MRK-560 represents an exception as it is largely tolerable in vivo despite displaying only a small selectivity between A beta production and Notch signaling in vitro. In exploring the molecular basis for the observed tolerability, we show that MRK-560 displays a strong preference for the presenilin 1(PS1) over PS2 subclass of gamma-secretases and is tolerable in wild-type mice but causes dose-dependent Notch-related side effect in PS2-deficient mice at drug exposure levels resulting in a substantial decrease in brain A beta levels. This demonstrates that PS2 plays an important role in mediating essential Notch signaling in several peripheral organs during pharmacological inhibition of PS1 and provide preclinical in vivo proof of concept for PS2-sparing inhibition as a novel, tolerable and efficacious gamma-secretase targeting strategy for AD.
|
|
| 9. |
- Borgegård, Tomas, et al.
(författare)
-
Alzheimer's Disease : Presenilin 2-Sparing γ-Secretase Inhibition Is a Tolerable Aβ Peptide-Lowering Strategy
- 2012
-
Ingår i: Journal of Neuroscience. - 0270-6474 .- 1529-2401. ; 32:48, s. 17297-17305
-
Tidskriftsartikel (refereegranskat)abstract
- γ-Secretase inhibition represents a major therapeutic strategy for lowering amyloid β (Aβ) peptide production in Alzheimer's disease (AD). Progress toward clinical use of γ-secretase inhibitors has, however, been hampered due to mechanism-based adverse events, primarily related to impairment of Notch signaling. The γ-secretase inhibitor MRK-560 represents an exception as it is largely tolerable in vivo despite displaying only a small selectivity between Aβ production and Notch signaling in vitro. In exploring the molecular basis for the observed tolerability, we show that MRK-560 displays a strong preference for the presenilin 1 (PS1) over PS2 subclass of γ-secretases and is tolerable in wild-type mice but causes dose-dependent Notch-related side effect in PS2-deficient mice at drug exposure levels resulting in a substantial decrease in brain Aβ levels. This demonstrates that PS2 plays an important role in mediating essential Notch signaling in several peripheral organs during pharmacological inhibition of PS1 and provide preclinical in vivo proof of concept for PS2-sparing inhibition as a novel, tolerable and efficacious γ-secretase targeting strategy for AD.
|
|
| 10. |
- Sehgelmeble, Fernando, et al.
(författare)
-
Sulfonimidamides as Sulfonamides Bioisosteres : Rational Evaluation through Synthetic, in Vitro, and in Vivo Studies with γ-Secretase Inhibitors
- 2012
-
Ingår i: ChemMedChem. - : Wiley. - 1860-7179 .- 1860-7187. ; 7:3, s. 396-399
-
Tidskriftsartikel (refereegranskat)abstract
- The proof of the pudding: A proof-of-concept study using γ-secretase inhibitors as a model has shown that sulfonimidamides act as bioisosteres for sulfonamides. Detailed in vitro and in vivo profiling reveal that the sulfonimidamide motif imparts desirable properties such as decreased lipophilicity and plasma protein binding, accompanied by increased solubility. Our data support a wider use of this unique functional group in the design of new pharmacologically active agents.
|
|
